IN8bio shares surge 11.00% premarket on $40.2M financing and durable GBM survival data.

IN8bio (INAB) surged 10.99% in premarket trading following the release of its fourth-quarter and full-year 2025 financial results, a $40.2 million private placement, and updated clinical data for its glioblastoma (GBM) programs. The company reported a 36% reduction in full-year net loss, a $27.1 million cash balance (up from $11.1 million in 2024), and a $20.1 million initial closing of a private placement to fund GBM and T cell studies through 2027. Notably, repeat-dose DeltEx DRI γδ T cell therapy in newly diagnosed GBM patients demonstrated a 97% improvement in median progression-free survival (13.0 vs. 6.6 months) and durable outcomes, reinforcing the therapy’s potential. The updated data, combined with a strengthened balance sheet and pipeline advancements, including a promoted COO, positioned IN8bio for key 2026 milestones, driving investor optimism.